Kodiak Sciences Inc
K27
Company Profile
Business description
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
Contact
1200 Page Mill Road
Palo AltoCA94304
USAT: +1 650 281-0850
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
113
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,833.60 | 4.90 | 0.06% |
| CAC 40 | 7,735.96 | 2.46 | -0.03% |
| DAX 40 | 23,809.32 | 19.21 | 0.08% |
| Dow JONES (US) | 44,484.42 | 10.52 | -0.02% |
| FTSE 100 | 8,819.52 | 44.83 | 0.51% |
| HKSE | 24,069.94 | 151.47 | -0.63% |
| NASDAQ | 20,393.13 | 190.24 | 0.94% |
| Nikkei 225 | 39,785.90 | 23.42 | 0.06% |
| NZX 50 Index | 12,704.48 | 79.81 | -0.62% |
| S&P 500 | 6,227.42 | 29.41 | 0.47% |
| S&P/ASX 200 | 8,595.80 | 1.90 | -0.02% |
| SSE Composite Index | 3,461.15 | 6.36 | 0.18% |